BLCO

MKT CAP:$6B

Bausch + Lomb Corporation

Market Cap

$6B

Healthcare·Medical - Instruments & Supplies·🇨🇦 Canada·NYSE

Healthcare·Medical·🇨🇦·NYSE

Stock Price

$15.82-$0.76 (-4.58%)

Apr 24, 2026

Company Details

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides con...

CEO

Brenton L. Saunders

IPO Date

May 6, 2022

Website

www.bausch.com

Key Metrics TTM

Revenue

$4.8B

+41.2% YoY

Net Income

-$299M

EPS (Diluted)

-$0.84

Free Cash Flow

$94M

Revenue / Share

$13.62

Gross Margin

58.5%

Operating Margin

4.6%

Net Margin

-6.2%

FCF Margin

2.0%

P/S

1.2x

P/E

—

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Feb 18, 2026

$3.8BEPS -$0.84

Q4 2025

Feb 18, 2026

$1.4BEPS -$0.16

Q3 2025

Oct 29, 2025

$1.3BEPS -$0.08

Q1 2025

Apr 30, 2025

$1.1BEPS -$0.60

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 20	$776M	$484M	$28M
Q2 20	$776M	$484M	$28M
Q3 20	$916M	$586M	$121M
Q4 20	$944M	$574M	$83M
Q4 22	$996M	$576M	$51M
Q1 25	$1.1B	$655M	-$83M
Q3 25	$1.3B	$771M	$95M
Q4 25	$1.4B	$816M	$158M

Valuation

Quarter	P/S	P/E
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q4 20	1.6x	—
Q4 22	1.5x	—
Q1 25	1.4x	—
Q3 25	1.3x	—
Q4 25	1.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 20	$92M	$37M
Q2 20	$92M	$37M
Q3 20	$204M	$137M
Q4 20	$134M	$55M
Q4 22	$148M	$103M
Q1 25	-$25M	-$135M
Q3 25	$139M	$65M
Q4 25	$134M	$62M

Capital Expenditures

Quarter	CapEx
Q1 20	$56M
Q2 20	$56M
Q3 20	$67M
Q4 20	$79M
Q4 22	$45M
Q1 25	$110M
Q3 25	$75M
Q4 25	$73M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	+28.4%	+26.3%
Q1 25	+46.5%	+63.1%
Q3 25	+39.8%	+49.2%
Q4 25	+48.8%	+44.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 20	$13M	1.6%
Q2 20	$13M	1.6%
Q3 20	$13M	1.4%
Q4 20	$12M	1.3%
Q4 22	$0	0.0%
Q1 25	$28M	2.5%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 20	$63M	$305M
Q2 20	$63M	$305M
Q3 20	$61M	$312M
Q4 20	$77M	$331M
Q4 22	$78M	$386M
Q1 25	$86M	$563M
Q3 25	$95M	$528M
Q4 25	$94M	$564M

Revenue Segments

Quarter	Product	Product and Service, Other	Branded and Other Generic Products	Device Products	Other Revenues	Over the Counter Products	Pharmaceutical Products
Q4 22	$991M	$5M	—	—	—	—	—
Q1 25	—	—	$54M	$448M	$4M	$409M	$222M
Q3 25	—	—	$59M	$484M	$4M	$454M	$280M
Q4 25	—	—	$72M	$518M	$7M	$489M	$319M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$190M	$0	$190M
Q2 22	$437M	$0	$437M
Q3 22	$287M	$0	$287M
Q4 22	$380M	$0	$380M
Q1 23	$346M	$0	$346M
Q2 23	$384M	$0	$384M
Q3 23	$360M	$0	$360M
Q4 23	$334M	$0	$334M
Q1 24	$325M	$0	$325M
Q2 24	$302M	$0	$302M
Q3 24	$329M	$0	$329M
Q4 24	$305M	$0	$305M
Q1 25	$202M	$0	$202M
Q2 25	$272M	$0	$272M
Q3 25	$310M	$0	$310M
Q4 25	$383M	$0	$383M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 20	350M	—	—
Q2 20	350M	0.0%	—
Q3 20	350M	0.0%	—
Q4 20	351M	+0.4%	—
Q4 22	350M	-0.4%	0.0%
Q1 25	353M	+0.8%	+0.8%
Q3 25	354M	+0.4%	+1.2%
Q4 25	354M	-0.1%	+0.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 20	—	—
Q2 20	—	—
Q3 20	—	—
Q4 20	—	—
Q4 22	$245.9K	4K
Q1 25	$84.2K	14K
Q3 25	$94.9K	14K
Q4 25	$108.1K	13K

Revenue / Employee